Table 2 Factors influencing the outcome of sunitinib therapy in all patients

Specifications of analyzed patients N = 99

PFS-HR (95% CI)

p

OS-HR (95% CI)

p

Age

1.012 (0.987–1.038)

0.351

1.007 (0.981–1.035)

0.590

Number of metastatic organs

1.083 (0.891–1.317)

0.423

1.100 (0.896–1.350)

0.364

PFS-HR (95% CI)

p

OS-HR (95% CI)

p

 man/ woman

1 / 1.367 (0.807–2.316)

0.245

1 / 1.388 (0.792–2.435)

0.252

 0 / 1 / 2

1 / 3.770 (1.345–28.435) / 6.693 (1.813–49.061)

0.019

1 / 2.692 (1.355–20.445) / 5.199 (1.713–37.929)

0.023

 Yes / No

1 / 1.492 (0.947–2.506)

0.065

1 / 1.553 (0.963–2.504)

0.071

 Yes / No

1 / 2.702 (1.508–4.840)

0.001

1 / 3.189 (1.741–5.842)

< 0.001

 Yes / No

1 / 2.665 (1.486–4.780)

0.001

1 / 3.157 (1.613–6.179)

0.001

 Yes / No

1 / 2.569 (1.437–4.595)

0.001

1 / 2.444 (1.288–4.636)

0.006

 2 / 1 / 0

NA

NA

1 / 7.731 (2.318–25.787) / 4.043 (1.228–13.311)

0.001